GlassScriptPhysician profile
Brett C Davis
NPI 1396774782
$4,383.42
in general payments reported to CMS, 2019-2025
26 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $415 · 2021: $562 · 2022: $635 · 2023: $536 · 2024: $794 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,749.66 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $658.22 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.22 | 2019-2025 | Xifaxan |
| Pfizer INC. | $312.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $272.94 | 2022-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $195.74 | 2019-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $89.80 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $83.07 | 2020-2024 | |
| Nestle Healthcare Nutrition INC. | $78.43 | 2022-2023 | |
| Ardelyx, INC. | $78.19 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $68.64 | 2024 | Voquezna |
| Allergan, INC. | $64.21 | 2019 | |
| Ironwood Pharmaceuticals, INC | $54.92 | 2021-2022 | |
| Braintree Laboratories, INC. | $42.57 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $37.29 | 2025 | Vowst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $37.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.58 | 2023-2024 | Cyltezo |
| Gilead Sciences, INC. | $28.09 | 2019-2020 | |
| Sandoz INC. | $15.63 | 2024 | Hyrimoz |
| Sanofi Pasteur INC. | $15.33 | 2021 | |
| Amgen INC. | $13.40 | 2020 | |
| Albireo Pharma, INC. | $13.27 | 2024 | Iqirvo |
| Daiichi Sankyo INC. | $12.86 | 2021 | |
| Merck Sharp & Dohme LLC | $11.35 | 2019 | |
| Boston Scientific Corporation | $11.20 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $10.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.